In-Person Access Only | TBD CE/CME Credits & MOC Points

All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $50 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team.

Total Health, in partnership with the European Society for Medical Oncology (ESMO)—a global authority representing more than 40,000 oncology professionals— is proud to present a state-of-the-art program designed to deliver exclusive U.S.-based updates from the ESMO Breast Cancer Symposiums, as well as the 2025 ESMO Annual Congress.

This free, 1-day symposium for healthcare providers will spotlight the most important advances across the breast cancer continuum.

Conference Agenda
Saturday, May 16, 2026

7:30 AM

Coffee and Exhibits

8:00 AM

Program Chair Welcome

8:10 AM

Neoadjuvant IO in TNBC

8:30 AM

Escalation vs de-escalation (HER2+, ER+)

8:50 AM

MRD/ctDNA in early breast cancer

9:10 AM

Endocrine therapy & next-gen SERDs

9:30 AM

Breakfast and Exhibits

9:45 AM

Non-CME Breakfast

10:30 AM

CDK4/6 inhibitors across disease stages

10:50 AM

HER2-low and ultralow categories (ADC expansion)

11:10 AM

Survivorship and QOL

11:30 AM

Emerging ADCs and novel targets in metastatic

disease (e.g. B7‑H4, Trop‑2 ADCs beyond T-DXd)

11:50 AM

Lunch and Exhibits

12:05 PM

Non-CME Lunch - Pfizer

12:50 PM

Housekeeping and Survey

1:00 PM

Mechanisms of resistance to HER2-directed therapies

& strategies to overcome (bispecifics, switching, combination strategies)

1:20 PM

Biomarkers beyond ctDNA: TILs, immune signatures, tumor microenvironment in breast cancer

1:40 PM

Liquid biopsy–guided therapeutic escalation

(e.g. ESR1 mutation detection, early switch strategies)

2:00 PM

PI3K/AKT pathway inhibition: new agents, sequencing, combination strategies

2:20 PM

AI / radiomics / imaging biomarkers in breast cancer

(predictive models, virtual biopsies)

2:40 PM

Break and Exhibits

2:55 PM

Management of brain metastases in HER2+ and triple-negative breast cancer

3:15 PM

Special populations: pregnancy-associated breast cancer,

male breast cancer, BRCA mutation carriers

3:35 PM

Panel Discussion

4:35 PM

ADJOURN

Agenda Subject To Change. All times are PST.

• Learning Objectives

  • Summarize recent advances in the diagnosis, staging, and treatment of breast cancer.  

  • Interpret emerging clinical trial data and its implications for current oncology practice. 

  • Enhance collaboration across the multidisciplinary cancer care team to improve patient outcomes. 

• Accreditation Information | TBD

  TBD - Coming soon!

• What to Expect | In-Person Learners

  • Free registration for all healthcare providers

  • Expert sessions that present the most clinically relevant data, research, and clinical strategies

  • Enduring video content for watching at your leisure

  • Real-time discussion and debate

  • Networking with peers, colleagues, and medical professionals

  • Access to the latest industry information and resources

  • Catered meals through-out the program